HR-5162-119
Referred to the House Committee on Energy and Commerce.
Sponsored by Haley Stevens (D-MI)
What it does
This bill would authorize HHS, through the CDC, to award competitive 5-year grants to states, territories, and the District of Columbia to fund outreach, education, and early detection efforts for colorectal cancer in individuals under 45. States could use the funds for screening support, diagnostic referrals, public awareness campaigns, provider training, patient navigation, and data monitoring, with unspent funds returned to the federal government after the grant period.
Who benefits
Individuals under 45 at elevated risk of colorectal cancer (those with family history, inflammatory bowel disease, or inherited syndromes), underserved and rural populations, American Indian, Alaska Native, and African American communities, people with type 2 diabetes, state health departments, hospitals, clinics, Tribal organizations, nonprofits, and universities that partner on grant-funded programs, and healthcare providers who receive training funded by the grants.
Who is hurt
No group bears direct costs beyond federal taxpayers funding the grant program; states that do not apply for or win competitive grants would not benefit relative to those that do, potentially creating uneven access to funded programs across states. Federal agencies would bear modest administrative costs to run the grant competition and oversight.
Supporters argue
Supporters argue that colorectal cancer is rising sharply among people under 50, with cases in the 20-39 age group projected to increase 90 percent by 2030, and that current screening guidelines starting at 45 miss many symptomatic younger patients. They contend targeted grants for education and early detection could catch cases earlier, potentially saving lives and reducing long-term treatment costs, particularly among high-risk and underserved populations identified in the bill.
Opponents argue
Opponents argue that competitive grant programs often favor states with more sophisticated grant-writing capacity, potentially leaving under-resourced states and the populations they serve without funded programs despite equal need. They contend that without mandatory appropriations or guaranteed funding levels, this bill only authorizes the program without ensuring dollars actually flow, and that a discretionary five-year federal grant may fail to address underlying access barriers like insurance coverage and provider shortages in rural areas.
Constitutional context
Congress may fund this program under the Taxing and Spending Clause (Article I, Section 8, Clause 1), which broadly permits spending for the general welfare, including grants to states for public health purposes. Because state participation is voluntary and competitive rather than compelled, this bill does not raise the coercion concerns addressed in NFIB v. Sebelius regarding conditional federal funding.
Checks and balances
Congress would authorize the grant program and appropriate funds in a separate process, while HHS and the CDC gain administrative authority to set application criteria, select grantees, and enforce reporting requirements, with oversight remaining subject to congressional appropriations and review.
Historical precedent
The CDC has long administered similar competitive state grant programs for cancer screening and prevention, such as the National Breast and Cervical Cancer Early Detection Program established in 1990.